RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Investor Forum, which will be held in San Francisco, CA from October 17-18, 2023. GeneVentiv will meet with prospective investors and present GENV-HEM, GeneVentiv’s lead AAV-based gene therapy which has an FDA Orphan Drug Designation for hemophilia A or B with or without inhibitors.
About GeneVentiv Therapeutics
GeneVentiv Therapeutics is a preclinical gene therapy company focused on identifying, in-licensing, and developing transformative genetic medicines for diseases with significant unmet needs. GeneVentiv is advancing two first-in-class programs. GENV-HEM is a liver-directed gene therapy designed to provide activated Factor V (FVa) for patients with hemophilia A, with or without FVIII inhibitors. GENV-002 is an in vivo gene-editing therapy for both infantile-onset (IOPD) and late-onset (LOPD) Pompe disease, designed to stably integrate a functional GAA transgene and establish the liver as a durable source of GAA enzyme.
Together, these programs are designed to address serious diseases where significant unmet needs remain.
Explore, learn more and grow with us.
← Back to Media